Sierra Oncology

June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Does amount matter when it comes to a biotech IPO?

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Where is the IPO class of 2014-15 now?

Select small caps stand out amid wider 2016 stock market declines

Patience rewards Ionis and Ziarco

Returns hint at gradual decline in quality of biotech floats

Lively M&A scene keeps biotech shares buoyant in Q3

Genmab and Tesaro lead first-half gainers as Endo and Infinity falter

Bristol-Myers buys back Medarex discard

Asco event analyser – 2016’s winners and losers

Biotech IPOs slow, but appetite for size remains unsatisfied

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Shock revelation sees Biogen erase its aducanumab losses

Vertex’s double cystic fibrosis surprise

Bristol might play a role in front-line lung cancer after all

Bloated on arrival? Biotech's weightiest new issues

Uncovering biopharma’s hidden treasures